Edwards Lifesciences Corp (EW)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	4,487,200	4,570,800	4,609,800	4,708,900	4,625,000	4,538,200	4,472,900	4,390,200	4,302,000	4,231,800	4,165,100	4,102,300	3,983,600	3,858,800	3,720,200	3,365,300	3,305,700	3,298,200	3,239,900	3,336,000
Revenue (ttm)	US$ in thousands	5,724,300	5,872,600	5,999,100	6,143,400	6,004,800	5,819,000	5,657,100	5,500,800	5,382,400	5,363,800	5,355,000	5,357,100	5,232,500	5,094,500	4,925,200	4,474,200	4,386,300	4,368,700	4,321,800	4,483,700
Gross profit margin		78.39%	77.83%	76.84%	76.65%	77.02%	77.99%	79.07%	79.81%	79.93%	78.90%	77.78%	76.58%	76.13%	75.74%	75.53%	75.22%	75.36%	75.50%	74.97%	74.40%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $4,487,200K ÷ $5,724,300K
= 78.39%

The gross profit margin for Edwards Lifesciences Corp has shown a general increasing trend over the past few years, indicating efficient management of production costs and pricing strategies. Starting at 74.40% in March 2020, the gross profit margin steadily improved to reach 78.39% by December 2024. This upward trajectory suggests that the company has been able to maintain healthy margins while potentially increasing sales or improving operational efficiency. However, there was a slight dip in the gross profit margin in the first quarter of 2024, decreasing from 79.93% in December 2022 to 76.65%, before recovering to 78.39% by the end of December 2024. It would be important for stakeholders to monitor this metric closely to ensure continued profitability and sustainable growth for the company.